Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Sleep Disorder Clinical Trial

Official title:

A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00199446
• Other study ID #: 6002-US-201
• Status: Completed
• Phase: Phase 2
• Start date: July 2005
• Est. completion date: October 2006

Study information

• Verified date: April 2024
• Source: Kyowa Kirin Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.

Description:

Restless Legs Syndrome (RLS) is a very common neurological disorder with a prevalence of approximately 10% in the adult population. It is characterized by an almost irresistible urge to move the legs, usually accompanied by feelings of intense discomfort. The feelings are usually present while at rest and are temporarily relieved by activity. Symptoms are worse in the evening and at night and lead to profound sleep disturbance and daytime fatigue. Although a number of therapeutic approaches have been used to treat the symptoms of RLS, none have been universally adopted. While it has been shown that some dopaminergic anti-parkinsonian medications are effective in treating RLS, their use may be somewhat limited by side effects associated with long-term dopaminergic activation. Istradefylline may provide a nondopaminergic approach to the treatment of RLS. This study will compare the efficacy of 40 mg per day of istradefylline in improving the symptoms of RLS with placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: October 2006
• Est. primary completion date: August 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

RLS that is mild to moderate in severity, non-nursing and non-pregnant if female, with an otherwise normal examination. Exclusion Criteria: Unable to stop other RLS medication, treatment with excluded medications, abnormal medical status.

Related Conditions & MeSH terms

• Parasomnias
• Psychomotor Agitation
• Restless Legs Syndrome
• Sleep Disorder
• Sleep Wake Disorders
• Syndrome

Intervention

Drug:
• Istradefylline (KW-6002)

Locations

Country	Name	City	State
United States	Kyowa Pharmaceutical Inc.	Princeton	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Kyowa Kirin, Inc.	Kyowa Kirin Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in an RLS rating scale score at endpoint (6 weeks of treatment or early discontinuation).
Secondary	Change from baseline values in an RLS rating scale score, in the a sleepiness scale, in values for Clinical Global Impression, in quality of life, and in actigraphic measurements.
Secondary	Safety